Lin BioScience, Inc.
6696
Rangering i aksjer
#3907
Lin BioScience, Inc. is an innovative biopharmaceutical company focused on... Lin BioScience, Inc. is an innovative biopharmaceutical company focused on developing novel therapies across oncology, ophthalmology, and metabolic diseases. Its robust pipeline includes LBS-008, an orally administered treatment currently in Phase 3 clinical trials for adolescent Stargardt disease (STGD1) and Phase 2/3 trials for dry age-related macular degeneration (Dry AMD), both aimed at evaluating its safety and effectiveness. Other key candidates are LBS-007, a natural non-ATP CDC7 inhibitor designed to combat various cancers; LBS-002, an anti-tubulin compound targeting primary and metastatic brain tumors; and LBS-009, an oral medication for non-alcoholic fatty liver disease and Type 2 diabetes. The company is headquartered in Taipei, Taiwan.
Aksjekurs
$5.03
Markedsverdi
$4.17B
Endring (1 dag)
-5.81%
Endring (1 år)
-44.72%
Land
TW
Handel Lin BioScience, Inc. (6696)
Kategori
Healthcare
Aksjeprishistorikk for Lin BioScience, Inc. (6696)
Høyeste sluttskurs: $5.40 den 2026-10-01
Laveste sluttskurs: $1.30 den 2018-10-01
Laveste sluttskurs: $1.30 den 2018-10-01
Aksjeprishistorikk for Lin BioScience, Inc. fra 2018 til 2026
Årlig aksjeprisytelse
| År | Ytelse |
|---|---|
| 2026 (TTM) | -4.14% |
| 2025 | 202.95% |
| 2024 | 13.59% |
| 2023 | -31.65% |
| 2022 | -22.82% |
| 2021 | 101.12% |
| 2020 | 278.57% |
| 2019 | -21.27% |
| 2018 | 0.00% |
Aksjepris for lignende selskaper eller konkurrenter
| Selskap | Aksjepris | Endring 1år% | Land |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $757.48 | 7.66% |
CH
|
